Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial*

Introduction SSc-ILD progression is variable and unpredictable, but observational studies have identified patient characteristics that may be prognostic of a greater FVC decline in SSc-ILD. We used placebo data of the SENSCIS trial to conduct a preliminary analysis of whether baseline variables were prognostic of a greater FVC decline over 52 weeks. Methods SENSCIS enrolled SSc-ILD patients with onset of first non-Raynaud symptom ≤7 years before screening, fibrotic ILD ≥10% on HRCT and FVC ≥40% predicted. Prednisone ≤10 mg/day (or equivalent) and/or stable therapy with mycophenolate or methotrexate for ≥6 months prior to randomization were allowed. Patients were randomized to nintedanib or placebo until the last patient had reached week 52 but for ≤100 weeks. We used data from placebo to investigate baseline characteristics as prognostic factors for a greater FVC decline (mL/year) over 52 weeks (Table). Our analyses were based on a random coefficient regression model with effects of anti-topoisomerase I antibody status, sex, time, baseline FVC (mL), age, height and subgroup-by-time and baseline-by-time interactions. Results 288 patients received placebo, 73.6% were female, 61.5% ATA-positive, and 50.7% had diffuse cutaneous SSc. At baseline, mean (SD) age was 53.4 (12.6) years, FVC 72.7 (16.6) % predicted and modified Rodnan skin score 10.9 (8.8); median time since first non-Raynaud’s symptom was 3.5 years; almost half (48.6%) were taking mycophenolate. In the primary analysis, the adjusted rate (SE) of FVC decline in placebo group was -93.3 (13.5) mL/year. None of the baseline factors was prognostic (p<0.05) of a greater FVC decline (mL/year) over 52 weeks, but baseline FVC ≤70% predicted and not taking mycophenolate showed trends toward being prognostic factors (Table). Conclusion Among SSc-ILD patients who received placebo in SENSCIS, no baseline characteristic was found to be prognostic of a greater FVC decline over 52 weeks, although baseline FVC ≤70% predicted and not taking mycophenolate showed trends. This supports previous studies suggesting that the course of SSc-ILD is difficult to predict, that prognostic factors identified in certain populations may not apply to all populations with SSc-ILD, and that new parameters or a combination of factors from different disease domains might be needed. Previously presented at ACR 202,

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.